Alfred Lammens

ProterixBio (United States) — United States

Medicine · Health Sciences

20h-index2.3kcitations40works10.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(6), DNA Repair Mechanisms(4), Glycosylation and Glycoproteins Research(4), Cell Adhesion Molecules Research(4), Chronic Lymphocytic Leukemia Research(4)

Publications40 total

The Discovery of Bridged Benzoazepine Amides as Selective Allosteric Modulators of RIPK1
ACS Medicinal Chemistry Letters·2025· 1 cited
Sulphostin-inspired N-phosphonopiperidones as selective covalent DPP8 and DPP9 inhibitors
Nature Communications·2025· 7 citedOpen Access
Identification of TAK-756, A Potent TAK1 Inhibitor for the Treatment of Osteoarthritis through Intra-Articular Administration
Journal of Medicinal Chemistry·2024· 2 cited
Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of MASH
Journal of Medicinal Chemistry·2024· 32 citedOpen Access
Structures, functions and adaptations of the human LINE-1 ORF2 protein
Nature·2023· 109 citedOpen Access
Biophysical and structural characterization of the impacts of MET phosphorylation on tepotinib binding
Journal of Biological Chemistry·2023· 4 citedOpen Access
A Phenotypic Screen Identifies Potent DPP9 Inhibitors Capable of Killing HIV-1 Infected Cells
ACS Chemical Biology·2022· 27 cited
Utilization of Metabolite Identification and Structural Data to Guide Design of Low-Dose IDO1 Inhibitors
ACS Medicinal Chemistry Letters·2021· 9 citedOpen Access
Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme
Journal of Medicinal Chemistry·2021· 25 citedOpen Access
Novel irreversible covalent BTK inhibitors discovered using DNA-encoded chemistry
Bioorganic & Medicinal Chemistry·2021· 42 citedOpen Access
Carbamate and <i>N</i>-Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 Inhibitors
ACS Medicinal Chemistry Letters·2021· 25 citedOpen Access
Activation of the IRE1 RNase through remodeling of the kinase front pocket by ATP-competitive ligands
Nature Communications·2020· 40 citedOpen Access
Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors
ACS Medicinal Chemistry Letters·2020· 82 citedOpen Access
HUMAN JAK3 IN COMPLEX WITH LASW959 PROTEIN IN COMPLEX WITH LIGAND
2018
Discovery of a Potent, Orally Bioavailable PI4KIIIβ Inhibitor (UCB9608) Able To Significantly Prolong Allogeneic Organ Engraftment <i>in Vivo</i>
Journal of Medicinal Chemistry·2018· 20 citedOpen Access
Crystal structure of human Phosphatidylinositol 4-kinase III beta (PI4KIIIbeta) in complex with ligand 44
2018
A loop region of BAFF controls B cell survival and regulates recognition by different inhibitors
Nature Communications·2018· 41 citedOpen Access
Crystal structure of human BAFF in complex with Fab fragment of anti-BAFF antibody belimumab
2017
IDO1/FXB-001116 crystal structure
2017
crystal structure of autotaxin in complex with PF-8380
2017
page 1 of 2Next →

Frequent Co-authors

Karl‐Peter Hopfner(14), K. Maskos(8), Guy Georges(6), Katja Lammens(5), Christian Klein(5), Pablo Umaña(5), Gerhard Niederfellner(5), Martin Augustin(5), Manfred Schwaiger(4), Xavier Fradera(4), Charles A. Lesburg(4), Karin M. Otte(4), Xuliang Jiang(4), Axel Kirchhofer(3), Ekkehard Mössner(3), Andreas G. Franke(3), Kornelius Wiechmann(3), Qinglin Pu(3), Hongjun Zhang(3), Mangeng Cheng(3)